Aimee DeGaetano Joins Vastrax as Global Head of Commercial and Clinical Affairs

Leading Clinical Research Organization Strengthens Expertise in Neurovascular Field


ANDOVER, Mass.–(BUSINESS WIRE)–Vastrax, a premier full-service Contract Research Organization (CRO) with a mission to expedite the development of cutting-edge technologies in the vascular market, proudly announces the appointment of Aimee DeGaetano as the Global Head of Commercial and Clinical Affairs.

“Our dedication to accelerating advancements in the vascular sector is unwavering, and Aimee’s appointment reinforces this commitment,” said Ryan Bouchard, President and CEO of Vastrax. “Aimee’s expertise aligns seamlessly with our mission, and we are thrilled to have her lead our Global Commercial Strategy and Clinical Affairs. Aimee’s appointment comes at a crucial juncture in Vastrax’s journey as we continue to lead the way in neurovascular clinical trials. Her expertise will significantly contribute to our efforts in helping our clients advance ground-breaking technological solutions that have the potential to transform the lives of patients worldwide.”

Aimee is a registered dietician (RD) and holds a master’s in public health (clinical epidemiology). She is currently completing a doctorate in health science at Eastern Virginia Medical School. She has held various leadership roles in medical technology companies, focusing on clinical trials, medical affairs, and key opinion leader engagement. Her unique blend of skills perfectly aligns with Vastrax’s multifaceted approach to driving efficient technology approvals.

“I am honored to contribute to Vastrax’s pivotal role in assisting our clients to expedite the introduction of groundbreaking vascular technologies,” commented Aimee DeGaetano. “Together, we will fortify our commitment to clinical trials, integrating novel innovations, strategies and technologies to enhance patient care and improve outcomes.”

About Vastrax, Inc.

Vastrax is a cutting-edge full-service Contract Research Organization specializing in expediting the development of cutting-edge technologies in the vascular market. With an expert team possessing over 100 years of combined clinical, commercial, and regulatory experience, Vastrax is at the forefront of pioneering innovations, delivering transformative products to market efficiently. For more information please visit us at www.vastrax.com and follow us on LinkedIn.

Contacts

Tara DiMilia

908-369-7168

Tara.DiMilia@tmstrat.com

Staff

Recent Posts

Teknova Announces Closing of $15.4 Million Private Placement

HOLLISTER, Calif., July 12, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a…

9 hours ago

Faith In Young Champions: Hisense Partners with UEFA Foundation to Bring the Beautiful Game to Hospitalized Children

QINGDAO, China, July 12, 2024 /PRNewswire/ -- During the EURO 2024 tournament, the global home…

18 hours ago

JANONE CONFIRMS NAME CHANGE TO ALT5 SIGMA CORPORATION AND NEW TICKER SYMBOL TO ALTS

LAS VEGAS, July 12, 2024 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a multidisciplinary organization with…

18 hours ago

Hospital Español Auxilio Mutuo De Puerto Rico, Inc. Reports Network Breach

Important Notice About a Privacy MatterSAN JUAN, PUERTO RICO / ACCESSWIRE / July 12, 2024…

18 hours ago

Nano Labs Announces Receipt of Deficiency Letters from Nasdaq

HANGZHOU, China, July 12, 2024 /PRNewswire/ -- Nano Labs Ltd (Nasdaq: NA) ("we," the "Company" or…

1 day ago

Inhance Technologies’ Statement in Response to EPA’s Section 6 Approach on Fluorination of Plastic Containers

HOUSTON, July 12, 2024 /PRNewswire/ -- Inhance Technologies welcomes the opportunity to engage with the…

1 day ago